In vitro anti-herpes simplex virus-2 activity of Salvia desoleana Atzei &amp; V. Picci essential oil by Cagno, Valeria et al.
RESEARCH ARTICLE
In vitro anti-herpes simplex virus-2 activity of
Salvia desoleana Atzei & V. Picci essential oil
Valeria Cagno1☯, Barbara Sgorbini2☯, Cinzia Sanna3, Cecilia Cagliero2, Mauro Ballero3,
Andrea Civra1, Manuela Donalisio1, Carlo Bicchi2, David Lembo1*, Patrizia Rubiolo2*
1 Laboratory of Molecular Virology, Department of Clinical and Biological Sciences, Università degli Studi di
Torino, Orbassano, Turin, Italy, 2 Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di
Torino, Torino, Italy, 3 Dipartimento di Scienze della Vita e dell’Ambiente, Università degli Studi di Cagliari,
Cagliari, Italy
☯ These authors contributed equally to this work.
* patrizia.rubiolo@unito.it (PR); david.lembo@unito.it (DL)
Abstract
Salvia desoleana Atzei & V. Picci is an indigenous species in Sardinia island used in folk
medicine to treat menstrual, digestive and central nervous system diseases. Nowadays, it is
widely cultivated for the pleasant smell of its essential oil (EO), whose antimicrobial and anti-
fungal activities have already been screened. This study evaluated the in vitro anti-Herpes
Simplex Virus-2 (HSV-2) activity of S. desoleana EO, fractions and main components: linalyl
acetate, alpha terpinyl acetate, and germacrene D. Phytochemical composition of S. deso-
leana EO was studied by GC-FID/MS analysis and the active fraction(s) and/or compounds
in S. desoleana EO were identified with a bioassay-guided fractionation procedure through
in vitro assays on cell viability and HSV-2 and RSV inhibition. S. desoleana EO inhibits both
acyclovir sensitive and acyclovir resistant HSV-2 strains with EC50 values of 23.72 μg/ml for
the former and 28.57 μg/ml for the latter. Moreover, a significant suppression of HSV-2 repli-
cation was observed with an EC50 value of 33.01 μg/ml (95% CI: 26.26 to 41.49) when the
EO was added post-infection. Among the fractions resulting from flash column chromatogra-
phy on silica gel, the one containing 54% of germacrene D showed a similar spectrum of
activity of S. desoleana EO with a stronger suppression in post-infection stage. These
results indicated that S. desoleana EO can be of interest to develop new and alternative
anti-HSV-2 products active also against acyclovir-resistant HSV-2 strains.
Introduction
Genital herpes is a sexually transmitted disease most commonly caused by herpes simplex
virus type 2 (HSV-2), a lipid-enveloped DNA virus belonging to the Herpesviridae family.
After the primary infection, HSV-2 establishes a lifelong latent infection in the lumbosacral
sensory ganglia. The reactivation can be triggered by several stimuli including immunosup-
pression, stress, and hormonal changes. As a result, asymptomatic episodes in which the virus
can be spread or recurrent painful ulcerations to the genital mucosa may occur, which, in turn,
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increase the risk of human immunodeficiency virus acquisition [1–3]. Besides the sexual trans-
mission, HSV-2 is correlated with a serious risk of mother to child infection during birth [4].
Currently, no vaccine is available but the antiviral drugs acyclovir, penciclovir and their
derivates, valacyclovir, and famciclovir are effective treatments for herpes simplex infections
[5,6]. These drugs are nucleoside analogues that interfere with viral DNA polymerization
shortening the course of the illness and decreasing the severity of the symptoms but are not
active in suppressing the latent infection. Moreover, due to their wide use, drug-resistant HSV
strains are nowadays common, particularly in immunocompromised patients [7].
For these reasons, it is still important to identify new antiviral substances (against HSV-2
acting with a different mechanism than nucleoside analogues to override the drug-resistance.
In this context, natural products could be rich sources of antiviral molecules due to their large
structural diversity and complexity [8]. Indeed, both plant extracts and essential oils have been
recently reported to inhibit HSV-2 infection [9–13].
Salvia desoleana Atzei & V. Picci [14,15] is an herbaceous perennial shrub belonging to
Lamiaceae family. It is endemic and exclusive of the island of Sardinia (Italy), but it is widely
cultivated because of its EO. The plant is 80–180 cm tall, with ovate leaves covered in both sur-
face by hairs and glands, releasing a strong fragrance when crushed or brushed. The inflores-
cences (30–50 cm) have hairy stems, with evenly spaced whorls of six flowers. The flowers
have a pale lavender upper lip, and an off-white trough-shaped lower lip. The plant blooms in
May-July and the fruits develop in September-November.
In Sardinian traditional medicine, the leaves of S. desoleana were used in decoction as anti-
pyretic, and in poultice and macerated as anti-inflammatory and to heal wounds [16].
A previous study showed a weak microbiostatic action of S. desoleana EO against S. aureus,
E. coli, S. epidermidis and C. albicans [17], however, no antiviral activity has been reported yet.
The present study was undertaken to test S. desoleana EO for its antiviral activity against HSV-
2, to investigate its probable mode of action and to identify its active ingredient(s). Interest-
ingly, among the pure compounds identified in the active fraction, several have been previ-
ously identified as inhibitors of HSV-1 infection [18–20].
Both the EO as such and an EO fraction enriched in its constituent germacrene D, proved
to be active against acyclovir-sensitive and acyclovir-resistant viral strains suppressing HSV-2
replication after virus attachment/entry.
Materials and methods
Materials
1,8 cineole, linalool and linalyl acetate with a purity> 97%, terpinyl acetate (mixture of two
isomers) with a purity> 95%; β-caryophyllene (mixture of two isomers) with a
purity> 98.5%,decane (purity >99%) high purity silica gel 70–230 mesh and silver nitrate on
silica gel (about 10% wt, % loading + 230 mesh) were from Sigma-Aldrich (Milan, Italy).
HPLC and analytical grade solvents were from Carlo Erba Reagenti (Rodano, Italy). Commer-
cially available standards were chosen to confirm component identification in the essential oil
and to quantify the EO components on the basis of their response factor towards an internal
standard (decane) considering the potential shift of FID towards the different classes of com-
pounds [21]. Acyclovir, used as a positive control for HSV-2 antiviral activity was purchased
from Sigma-Aldrich (Milan, Italy).
Essential oil (EO)
The aerial parts of S. desoleana (20 Kg) were harvested during the flowering period from Sadali
(CA), Sardinia (Italy) and derived from plants cultivated by the Consortium Fragus e saporis
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de Sardinia. The Consortium Fragus e saporis de Sardinia gave permission to conduct the
study on this site. The taxonomical identification was performed by Dr. Cinzia Sanna and a
voucher specimen (Herbarium CAG 1086) has been retained in the General Herbarium of the
botanical garden of the University of Cagliari. EO from fresh plant materials was obtained in
agreement with the European Pharmacopoeia VIII ed.: fresh crushed aerial parts were submit-
ted to steam distillation for five hours (h). The resulting EO were left to stabilize for one hour.
The yield in essential oil was 0.12% (v/w on fresh material).
Essential oil fractionation
S. desoleana EO (1.2 g) was fractionated on silica gel column chromatography using petroleum
ether with increasing amounts of ethyl acetate. Two main fractions (SD1 and SD2) were
obtained with 100% petroleum ether and 80/20 petroleum ether/ethyl acetate respectively.
Fraction SD1 represents the 25% of the total EO and mainly containing mono and sesquiter-
pene hydrocarbons. Fraction SD2, representing 59% of the total essential oil, mainly contained
oxygenated mono and sesquiterpenoids.
GC-FID-MS and enantioselective (ES)-GC-FID-MS analysis
GC analyses were carried out on a Shimadzu 2010 GC-FID system and a Shimadzu QP2010
plus GC-MS system, provided with an AOC-20i automatic injector. Data were processed with
Shimadzu GC Solution 2.53SU1 software and Shimadzu1224 PGCMS Solution 2.51 software,
respectively (Shimadzu, Milan, Italy).
GC-FID-MS analyses were carried out on a Mega 5 column (95% polydimethyl-siloxane,
5% phenyl) 25 m×0.25 mm dc ×0.25 μm df, from MEGA (Milan, Italy).
Analysis conditions were as follows: injection mode: split; split ratio: 1:20; injection volume:
1 μl. Temperatures: injector:250˚C, FID: detector: 280˚C, MS: transfer line:280˚C; ion source:
200˚C; carrier gas: He, initial flow rate 1.0 ml/min in constant linear velocity mode. The tem-
perature programme was from 50˚C (1 min) to 250˚C (10 min) at 3˚C/min (5˚C/min for
Mega-Dex DMT-Beta column). The MS was operated in electron impact ionization mode at70
eV, with a mass range of 35–350 m/z in full scan mode.
EO components were identified by comparison of both their linear retention indices (ITs),
calculated versus a C9-C25 hydrocarbon mixture, and their mass spectra to those of authentic
samples, or to those reported in commercially available mass spectral libraries [22].
Cells
African green monkey fibroblastoid kidney cells (Vero, ATCC CCL-81), the epithelial cell
lines Hep-2 (ATCC CCL-23) and A549 (ATCC CCL-185) were grown as monolayers in Eagle’s
minimal essential medium (MEM) (Gibco/BRL, Gaithersburg, MD) supplemented with 10%
heat inactivated fetal calf serum (FCS) and 1% antibiotic-antimycotic solution (Zell Shield,
Minerva Biolabs GmbH, Berlin, Germany).
Viruses
A clinical isolate of HSV-1 and HSV-2 were kindly provided by Prof. M. Pistello, University of
Pisa, Italy. HSV strains was propagated and titrated by plaque assay on Vero cells. A HSV-2
strain with phenotypic resistance to acyclovir was generated by serial passage in the presence
of increasing concentrations of acyclovir, as previously described [23]. Virus stocks were main-
tained at -80˚C. Respiratory syncytial virus (RSV) strain A2 (ATCC VR-1540) was propagated
in Hep-2 cells by infecting a freshly prepared confluent monolayer grown in MEM
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supplemented with 2% of FCS. When the cytopathic effect involved the whole monolayer, the
infected cell suspension was collected and the viral supernatant was clarified. The virus stocks
were aliquoted and stored at -80˚C. The infectivity of virus stocks was determined on Hep-2
cell monolayers by standard plaque assay.
Cell viability
Cell viability was measured using the MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxy- phenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay, as described by Civra et al. [24].
Confluent cell cultures seeded in 96-well plates were incubated with serially diluted EO, frac-
tions, constituents or acyclovir in triplicate under the same experimental conditions described
for the antiviral assays. The effect on cell viability at different concentrations was expressed as
a percentage, by comparing absorbances of treated cells with those of cells incubated with cul-
ture medium supplemented of equal volume of DMSO. The 50% cytotoxic concentrations
(CC50) and 95% confidence intervals (CIs) were determined using Prism software (Graph-Pad
Software, San Diego, CA).
HSV inhibition assays
The effect of S. desoleana EO, fractions, constituents or acyclovir on HSV infection was evalu-
ated by plaque reduction assay. Vero cells were pre-plated 24 h in advance in 24-well plates at
a density of 10 x 104 cells. Increasing concentrations of EO, fractions, constituents or acyclovir
were added to cells for two hours; a mixture of the different tested substances plus HSV-2 or
HSV-1 or acyclovir resistant HSV-2 (MOI 0.0005 pfu/cell) was subsequently added to the cells,
which were then incubated at 37˚C for two hours. The virus inoculum was then removed and
the cells washed and overlaid with a medium containing 1.2% methylcellulose (Sigma) and
serial dilutions of EO, fractions, constituents or acyclovir. For acyclovir antiviral assay the
compound was added only after infection, diluted in the medium containing methylcellulose
as described before. After further incubation at 37˚C for 24 hours, cells were fixed and stained
with 0.1% crystal violet in 20% ethanol and viral plaques counted. The concentration produc-
ing 50% reduction in plaque formation (EC50) was determined using Prism software by com-
paring drug-treated with untreated wells. Three independent experiments were performed in
duplicate.
Moreover, the plaques were visualized using a Leica inverted microscope equipped with a
Bresser MikroCam microscope camera and MikroCamLab software (Rhede, Germany). Ima-
geJ software was used to quantify plaque sizes. Untreated HSV2-infected monolayers were
used as the control.
RSV inhibition assay
To evaluate the ability to inhibit RSV infection, EO was serially diluted to generate dose-
response curves and added to cells. After 2 h, EO was removed and a mixture of EO dilutions
and RSV (MOI 0.01 PFU/cell) was added to A549 cells grown as monolayers in a 96-well plate
at a density of 7 x 104/well. After 3 hours of incubation at 37˚C, monolayers were washed and
overlaid with 1.2% of methylcellulose medium containing serial dilutions of EO. Three days
post-infection, cells were fixed with cold methanol and acetone for 1 min and subjected to
RSV-specific immunostaining using an RSV monoclonal antibody (Ab35958, Abcam, Cam-
bridge, UK) and the UltraTech HRP streptavidin-biotin detection system (Beckman Coulter,
Marseille, France). Immunostained syncytia were counted and the percent inhibition of virus
infectivity determined by comparing the number of plaques in treated wells with the number
in untreated control wells. 50% effective concentration (EC50) values and 95% CIs were
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determined using Prism software. All data were generated from duplicate wells in at least three
independent experiments.
Time-of-addition assay
Serial dilutions of EO or fraction SD1 were added to cells: two hours before infection (pre-
treatment assay), during infection, or post infection (post-treatment assay). After the incuba-
tion time, viral plaques were counted.
Virus inactivation assay
Approximately 105 PFU of HSV-2 plus EC90 of S. desoleana EO was added to MEM and
mixed in a total volume of 100 μl. The virus-EO mixtures were incubated for zero hours or
two hours at 37˚C then diluted serially to the non-inhibitory concentration of S. desoleana EO;
the residual viral infectivity was determined by viral plaque assay.
Data analysis
All results are presented as the mean values from three independent experiments performed in
duplicate. The EC50 values for inhibition curves were calculated by regression analysis using
the software GraphPad Prism version 4.0 (GraphPad Software, San Diego, California, U.S.A.)
by fitting a variable slope-sigmoidal dose—response curve. The selectivity index (SI) was calcu-
lated by dividing the CC50 by the EC50 value.
Results and discussion
Within a project aiming to investigate the potential antiviral activity of endemic plants from
Sardinia, this study evaluated the anti-HSV-2 activity of S. desoleana EO, fractions and its
main components. The EO was obtained by steam distillation of the fresh aerial part from cul-
tivated plants in order to obtain a more standardized product. Table 1 reports its chemical
composition. Thirty-four components were identified accounting for 95.8% of the EO and the
main components were linalyl acetate (30.2%), germacrene D (18.7%) and alpha terpinyl ace-
tate (16.8%). The qualitative EO composition here reported is coherent with those reported in
the literature and affords to differentiate S. desoleana from S. sclarea [17,25,26]. S. desoleana
EO composition was confirmed by the distillation of plants in different years from 2010 to
2013 (data not shown).
The EO anti-HSV-2 activity, was initially investigated by a complete protection assay in
which increasing EO concentrations were added to the cell culture before, during, and after
the infection to generate dose-response curves. Acyclovir was tested in parallel with EO as a
reference drug. As shown in Table 2, the EO EC50 value was equal to 23.72 μg/ml whereas the
CC50 was 1577 μg/ml with a SI of 66.48, indicating that the antiviral effect was not a conse-
quence of cytotoxicity. Of note, the EO antiviral activity was found to be independent on the
virus sensitivity to acyclovir as demonstrated by the EC50 value of 28.57 μg/ml against an acy-
clovir-resistant HSV-2 (Table 3) which is similar to that calculated for the acyclovir-sensitive
strain (Table 2).
The activity against an acyclovir-resistant HSV-2 strain suggests that the EO mode of action
differs from that of acyclovir, an interesting feature in light of a possible development of the
EO as an anti-HSV-2 treatment. Despite of antiviral activity of EO against HSV-2 infection, no
inhibitory activity was observed against the other member of Herpesviridae family, HSV-1
(data not shown).
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Next, the EO was tested against RSV, another lipid-enveloped virus belonging to a different
virus family (Paramyxoviridae) as HSV-2, to assess the specificity of EO antiviral action. Inter-
estingly, we could not observe any inhibition demonstrating that the EO antiviral activity is
virus-specific (data not shown).
To explore whether the EO directly inactivates HSV-2 particles, a virus inactivation assay
was performed with a not cytotoxic concentration of EO that reduces almost completely virus
infection (EC90). HSV-2 aliquots were therefore incubated with 190 μg/ml of EO for 0 hours
Table 1. Chemical composition (expressed as g/100g) of S. desoleana essential oil and its fractions.
# Compounds Itsexpa Itslitb EO SD1 fraction SD2 fraction
1 α-thujene 929 931 0.2 0.3
2 α-pinene 936 939 0.5 0.5
3 sabinene 975 976 1.0 1.3
4 β-pinene 977 980 1.2 2.7
5 myrcene 992 991 1.3 2.3
6 limonene 1028 1031 1.0 1.8
7 1,8-cineole 1033 1033 10.2 12.6
8 cis-β-ocimene 1042 1040 1.4 3.3
9 trans-β-ocimene 1052 1050 0.5 1.1
10 γ-terpinene 1061 1062 tr 0.2
11 α-terpinolene 1088 1088 0.2 0.5
12 linalool 1101 1098 5.1 8.1
13 terpinen-4-ol 1177 1177 0.2 0.4
14 α-terpineol 1190 1189 1.8 0.2
15 linalyl acetate 1260 1257 27.3 39.7
16 α-terpinyl acetate 1352 1350 17.5 30.1
17 neryl acetate 1367 1365 tr 0.1
18 α-copaene 1377 1376 0.7 1.6
19 β-bourbonene 1383 1384 0.3 0.9
20 geranyl acetate 1385 1383 tr 1.0
21 β-elemene 1392 1391 1.0 2.7
22 β-caryophyllene 1415 1418 1.3 4.8
23 aromadendrene 1437 1439 0.4 1.3
24 germacrene D 1479 1480 17.9 55.0
25 bicyclogermacrene 1492 1494 0.2 3.1
26 γ-cadinene 1512 1513 0.4 1.3
27 δ-cadinene 1522 1524 0.3 1.3
28 MW = 222 1613 / 0.2 0.5
29 MW = 222 1638 / 0.6 1.3
30 β-eudesmol 1648 1649 0.6 0.6
31 MW = 272 1928 / tr 0.7
32 MW = 272 1953 / 1.6 6.7
33 MW = 272 1966 / 0.4 2.1
34 MW = 272 1980 / 0.3 0.7
Total 95.8 96.2 96.5
a ITsexp: experimental linear retention index
bITslit: linear retention index from literature
tr: amount below 0.1g/100g
doi:10.1371/journal.pone.0172322.t001
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or 2 hours at 37˚C. After incubation, the samples were titrated on Vero cells at high dilutions,
at which residual EO was no longer active. As reported in Fig 1, this treatment did not produce
a significant loss of HSV-2 infectivity demonstrating that EO does not exert any direct effect
on viral particles.
This result indicates that the EO most probably targets cell-surface or intracellular events
involved in essential steps of the HSV-2 replicative cycle. Therefore, time-of-addition assays
was used to investigate which step(s) of the virus replicative cycle were affected by the EO (Fig
2). Since some antiviral compounds are known to lower cell susceptibility to viral infection by
downregulating or directly masking virus receptors, the EO was tested by a pre-treatment
assay. The results, deriving from three independent experiments, showed that different doses
of EO added 2 hours prior to virus infection and then washed out before virus inoculum did
not exert any inhibitory activity. Moreover, no inhibition was observed when the EO was
added during infection ruling out an inhibitory effect on virus attachment and/or entry. In
contrast, when it was added just after the virus inoculum and left throughout the assay, a sig-
nificant suppression of HSV-2 replication was observed with an EC50 value of 33.01 μg/ml.
Table 2. Antiviral activity against HSV-2.
EC50a 95% CIb (μg/ml) CC50c (μg/ml) SId
Total Essential oil 23.72 (16.09–34.97) 1577 66.48
SD1 10.69 (8.36–13.68) 58.11 5.44
SD2 n.a.e 358.2 n.a.
β-Caryophyllene 5.38 (3.42–8.47) 49.00 9.10
Terpinyl acetate n.a. 507.5 n.a.
Linalyl acetate n.a. 1014 n.a.
Linalool n.a. 989.6 n.a.
1,8-Cineole n.a. >1710 n.a.
Acyclovir 0.14 (0.098–0.21) 165 1178
aEC50: effective concentration 50%
bCI: confidence interval




Table 3. Antiviral activity against HSV-2 acyclovir resistant.
EC50a 95% CIb (μg/ml) CC50c (μg/ml) SId
Essential oil 28.57 (18.90–29.76) 1577 55.20
SD1 6.58 (5.79–7.48) 58.11 8.83
β-Caryophyllene 5.02 (3.55–7.10) 49.00 9.76
Acyclovir 71.84 (41.3–103.4) 165 2.29
aEC50: effective concentration 50%
bCI: confidence interval
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Interestingly, the EO not only significantly reduced the plaque number but also decreased the
area of the remaining plaques (Fig 2B and 2C).
Taken together, the results from the virus inactivation and time-of-addition assays indicate
that EO exerts its antiviral activity by inhibiting later steps of the virus replicative cycle (e.g.
uncoating, genome replication, virus assembly or exit, cell-to-cell spread). This effect can be
ascribable to several EO components acting together or to a single chemical species. To assign
the antiviral activity to specific fractions and/or to single components of S. desoleana EO a bio-
assay-guided fractionation procedure was adopted. Fraction SD1 was obtained with flash col-
umn chromatography on silica gel eluted with petroleum ether (100%). This fraction was
characterized by mono and sesquiterpene hydrocarbons where germacrene D was the most
abundant terpene hydrocarbon representing the 54% of the fraction; the second more abun-
dant component was beta-caryophyllene (4.8% of SD1 fraction). Fraction SD2 (80/20 petro-
leum ether/ethyl acetate) was characterized by the presence of a mixture of oxygenated
monoterpenes the most abundant are linalyl acetate, α-terpinyl acetate, 1,8 cineole and linalool
(Table 1). The two fractions SD1 and SD2 were tested along with the pure commercially avail-
able standards of 1,8 cineole, linalool, linalyl acetate and α-terpinyl acetate and β-
caryophyllene.
As shown in Table 2, SD1 was found to be the only active fraction with an EC50 of 10.69 μg/
ml; Neither SD2 nor the pure oxygenated monoterpenes tested exerted any antiviral activity.
SD1 fraction showed the same spectrum of activity of the EO not only against HSV-2, but
also against the acyclovir-resistant strain with an EC50 of 6.58 μg/ml (Table 3) and it was no
active against HSV-1 infection (data not shown). Furthermore, SD1 was active only when
added to the cells after virus inoculum in time-of-addition assays (Fig 3A) and, performing
post-treatment assay, it reduced the plaque number as well as the area of the remaining plaques
(Fig 3B and 3C) as previously observed with the EO (Fig 2B and 2C). These data suggested that
the antiviral effect of EO is totally due to SD1. Furthermore, SD1 inhibited viral infection in
post-treatment assay with lower value of EC50 (16 μg/ml) rather than the value of EC50 of EO
(33.01 μg/ml).
Interestingly, the pure commercially available standard of β-caryophyllene, a component of
SD1 fraction, inhibits both HSV-2 and acyclovir-resistant strain infections with similar lower
SI (9.10 and 9.76, respectively) in comparison with the EO (5.44).
Fig 1. Virus inactivation assay 105 pfu of HSV-2 were incubated with 190 μg/ml of S. desoleana EO for
0 or 2 h at 37˚C. The mixtures were then titrated on Vero cells at high dilutions at which the concentration of
EO was not active. The titers, expressed as pfu/ml, are means and SEM for 3 independent experiments
performed in duplicate.
doi:10.1371/journal.pone.0172322.g001
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Although the anti-HSV-2 activity of β-caryophyllene, we cannot exclude an antiviral role of
other components of SD1, present in higher amount as germacrene D or present in lower
quantities. Among the pure compounds identified in SD1 fractions, α-pinene, β-pinene, γ-ter-
pinene, limonene, and β-caryophyllene have been previously identified as inhibitors of HSV-1
infection by direct interaction with free virus particles [18–20]. However, other papers did not
evidence antiviral activity for α-pinene and β-caryophyllene against HSV-1 [27,28]. In accor-
dance with these papers, we also not evidenced antiviral activity for β-caryophyllene against
HSV-1 infection (data not shown). Moreover, β-myrcene, another component of SD1 fraction,
was already shown to be devoid of antiviral activity against HSV-1 infection [27,28]. Germa-
crene D is a common component of several essential oils but, to the best of our knowledge,
only one study concerning an ethanol extract of Cedrus libani leaves, containing a high per-
centage of germacrene D, reports results on tests against HSV-1 [27]. In fraction SD1, Germa-
crene D was the most abundant terpene hydrocarbon, however it is actually not available as
Fig 2. Time-of-addition assays with S. desoleana EO. A) Vero cells were treated with EO prior to virus
infection (pre-treatment), during the infection period (during infection), or after infection (post-treatment). Data
are presented as % of control. Values are means ± SEM of three independent experiments performed in
duplicate. B) The histograms show the percentage of plaque area and plaque number of treated wells
compared to that of untreated wells as a function of the concentration in the post-treatment assay. C) The
images show representative plaques in Vero cells. The pictures and histograms shown are representative of
many analyzed plaques, ranging from 15 to 25 per condition. * P< 0.0001.
doi:10.1371/journal.pone.0172322.g002
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commercial standard therefore further studies will be conducted to try to isolate it to verify if it
may be considered potentially active against HSV-2.
Conclusions
In conclusion, S. desoleana EO and SD1 fraction were here shown to be active against HSV-2
inhibiting a step of its replicative cycle that occurs after virus attachment and entry. Further
studies are required to elucidate the mechanism of antiviral action and to identify the cellular
and/or viral targets.
Anyway, the antiviral activity of S. desoleana EO and of the SD1 fraction against an acyclo-
vir-resistant HSV-2 strain is an additional interesting feature prompting further studies to
assess their potential in in vivo examinations.
Fig 3. Time-of-addition assays with SD1 fraction. A) Vero cells were treated with SD1 fraction prior to virus
infection (pre-treatment), during the infection period (during infection), or after infection (post-treatment). Data
are presented as % of control. Values are means ± SEM of three independent experiments performed in
duplicate. B) The histograms show the percentage of plaque area and plaque number of treated wells
compared to that of untreated wells as a function of the concentration in the post-treatment assay. C) The
images show representative plaques in Vero cells. The pictures and histograms shown are representative of
many analyzed plaques, ranging from 15 to 25 per condition. * P< 0.0001.
doi:10.1371/journal.pone.0172322.g003
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